{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:09:00Z","timestamp":1780452540405,"version":"3.54.1"},"reference-count":31,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Despite recent advances in the treatment of multiple myeloma (MM), the disease remains incurable. Agents targeting the programmed death-1 (PD-1) axis have become key treatments for many cancers; however, monotherapies with PD-1\/PD-L-1 inhibitors (PD-1i) have shown a limited efficacy in MM patients. We conducted a meta-analysis to evaluate the safety and efficacy of PD-1i in combination with standard of care (SOC) therapies for MM. Methods: A systematic search identified phase II and III randomized clinical trials involving MM patients treated with PD-1i, using terms such as \u201cRelapsed Multiple Myeloma\u201d and \u201cPD-1 inhibitors.\u201d The search included trials published in English after 2016 using the PubMed, CINAHL, and Cochrane databases. Data were analyzed using RStudio v4.4.2, with survival data assessed using Kaplan\u2013Meier methods and Cox proportional hazards analysis. Results: Our search yielded 19 total trials, of which 5 (representing 889 unique patients) met the criteria for inclusion. A total of 488 patients received PD-1i + SOC, and 401 received SOC alone. The median progression-free survival (PFS) was 6.26 months for the PD-1i + SOC group and 7.34 months for the SOC alone group (HR, 1.2; 95% CI: 0.95\u20131.41; p = 0.14). The median overall survival (OS) was 22.49 months for PD-1i + SOC compared to 24.38 months for SOC alone (HR, 1.11; 95% CI: 0.87\u20131.42, p = 0.36). The PD-1i group showed a higher incidence of all-grade pneumonia (RR = 1.44, 95% CI: 1.03\u20132.02, p = 0.03), grade \u2265 3 neutropenia (RR = 1.36, 95% CI: 1.00\u20131.85, p = 0.05), immune-mediated adverse events (RR = 10.1, 95% CI: 0.38\u2013271.1, p = 0.17), and grade \u2265 3 irAEs (RR = 9.59, 95% CI: 0.62\u2013148.8, p = 0.11). Conclusion: This analysis highlights the limited efficacy and increased toxicity of adding PD-1i to SOC in MM patients. Further research is needed to explore whether targeting the PD-1\/PD-L1 axis in combination with novel therapies can safely enhance the therapeutic efficacy in MM patients.<\/jats:p>","DOI":"10.3390\/cancers17233730","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:41:58Z","timestamp":1763728918000},"page":"3730","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Standard of Care with or Without a PD-1\/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials"],"prefix":"10.3390","volume":"17","author":[{"given":"Zain","family":"Alsaddi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, King Hussein Military Hospital, Jordanian Royal Medical Services, Amman 11855, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1027-554X","authenticated-orcid":false,"given":"Osama","family":"Younis","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Jordan, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-2905","authenticated-orcid":false,"given":"Ghena","family":"Khasawneh","sequence":"additional","affiliation":[{"name":"Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Shatnawi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra Mahmoud","family":"Jafari","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-0563","authenticated-orcid":false,"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6603-185X","authenticated-orcid":false,"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-8225","authenticated-orcid":false,"given":"Barry","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2024.12.002","article-title":"Real-World Treatment Patterns and Clinical Outcomes in Patients with Multiple Myeloma Previously Treated with Lenalidomide and an Anti-CD38 Monoclonal Antibody","volume":"25","author":"Ramasamy","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1182\/blood-2022-156225","article-title":"Treatment Patterns and Outcomes in Patients with Relapsed\/Refractory Multiple Myeloma Receiving \u22653 Lines of Therapy: A Real-World Evaluation in the United States","volume":"140","author":"Girvan","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Oliva, S., Troia, R., D\u2019Agostino, M., Boccadoro, M., and Gay, F. (2018). Promises and Pitfalls in the Use of PD-1\/PD-L1 Inhibitors in Multiple Myeloma. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02749"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jelinek, T., Paiva, B., and Hajek, R. (2018). Update on PD-1\/PD-L1 Inhibitors in Multiple Myeloma. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02431"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Liu, N., Zhou, Y., and Lee, J.J. (2021). IPDfromKM: Reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 21.","DOI":"10.1186\/s12874-021-01308-8"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10254","DOI":"10.1002\/cam4.5753","article-title":"Isatuximab in combination with cemiplimab in patients with relapsed\/refractory multiple myeloma: A phase 1\/2 study","volume":"12","author":"Lesokhin","year":"2023","journal-title":"Cancer Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Abdallah, A.O., Lesokhin, A., Wrobel, T., Jamroziak, K., Dytfeld, D., Touzeau, C., Suvannasankha, A., Leleu, X., Silbermann, R., and Khan, A.M. (2023). Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: Results of a randomized phase I\/II clinical trial. Front. Hematol., 2.","DOI":"10.3389\/frhem.2023.1244494"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.clml.2024.05.014","article-title":"Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study","volume":"24","author":"Oriol","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tips.2015.06.005","article-title":"New immunotherapies targeting the PD-1 pathway","volume":"36","author":"Chinai","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI98888","article-title":"Bone marrow transplantation generates T cell-dependent control of myeloma in mice","volume":"129","author":"Vuckovic","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/sj.onc.1206315","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB\/p50) in myeloma cells","volume":"22","author":"Landowski","year":"2003","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1038\/sj.onc.1203782","article-title":"Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)","volume":"19","author":"Hazlehurst","year":"2000","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1158\/1078-0432.CCR-20-2839","article-title":"VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival","volume":"27","author":"Fontana","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.1101649","article-title":"Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction","volume":"187","author":"Kastenmuller","year":"2011","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15384101.2018.1442624","article-title":"Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1\/PD-L1 pathway","volume":"17","author":"Chen","year":"2018","journal-title":"Cell Cycle"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jtct.2023.11.014","article-title":"PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy","volume":"30","author":"Mishra","year":"2024","journal-title":"Transplant. Cell Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3730\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:47:49Z","timestamp":1763729269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":31,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17233730"],"URL":"https:\/\/doi.org\/10.3390\/cancers17233730","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}